Depression is one of the most treatable conditions in medicine — but not for everyone on the first or even the second try. About one in three people who seek treatment for depression continue to struggle after two or more treatments with different antidepressant medications. When that happens, it’s called treatment-resistant depression. It doesn’t mean the depression is untreatable, and it doesn’t mean anything has been done wrong. It means it’s time for a different approach.
Our Treatment-Resistant Depression Program exists for exactly this point in the journey. We specialize in the treatments that come after standard medications and therapy — evidence-based interventions that work through the brain's circuitry and chemistry in fundamentally different ways than conventional antidepressants.
How we begin
Every patient’s first visit with us starts with a comprehensive diagnostic reassessment. Before recommending an advanced treatment, we take a careful second look: Is the diagnosis complete? Are bipolar disorder, trauma, substance use, sleep disorders, vitamin deficiencies, thyroid disease, chronic pain, or medication side effects contributing to the depression Were previous medication attempts given at the right dose for the right length of time? It is not uncommon for a person who has been labeled "treatment-resistant" to have actually never had a fully optimized medication treatment — and identifying that changes everything. We also use standardized symptom-rating scales throughout your treatment course so that progress is measured, not guessed at.
Treatments we offer
Transcranial magnetic stimulation (TMS).
A noninvasive, office-based treatment that uses focused magnetic pulses to stimulate mood-regulating brain circuits. No anesthesia, no sedation, no memory side effects — patients drive themselves home and return to work the same day. We offer both conventional daily protocols and newer, faster acting theta-burst approaches that compress treatment into a much shorter window.
Esketamine (Spravato®) and ketamine.
Rapid-acting treatments that work on the brain's glutamate system rather than serotonin. The glutamate system is the brain’s main “on” switch. Many patients notice improvement within hours to days rather than weeks to months. Esketamine is an FDA-approved nasal spray for treatment-resistant depression, often given alongside an oral antidepressant, and is delivered in our certified, monitored treatment suite.
Medication optimization.
At our Treatment Resistant Depression Program, we don’t take over prescribing medications from your current psychiatric prescriber. Instead, we can provide consultation on prior medication trials and offer carefully thought-out strategies using add-on medications, combinations, and, where appropriate, pharmacogenomic information — often in combination with an interventional treatment rather than instead of one. We are happy to work in collaboration with your current prescriber while you are receiving interventions in our clinic.
Whole-person care.
Attention to sleep, substance use, exercise, and other co-exisiting medical conditions you may have, is integrated with every treatment we offer. Interventional treatments work best when the rest of the picture is addressed too.
Treatments we evaluate for and make appropriate referrals for:
Electroconvulsive therapy (ECT). The most effective treatment available for severe depression, and a critical option when symptoms are life-threatening or a rapid response is needed. Modern ECT bears little resemblance to its portrayal in film: it is performed under brief anesthesia, with refined electrode placements and ultra-brief pulse techniques designed to preserve memory and thinking, and it is usually done on an outpatient basis.
Vagus nerve stimulation (VNS). An implanted device that delivers gentle, ongoing stimulation to a nerve pathway connected to mood-regulating brain regions. VNS is designed for long-term, chronic, difficult-to-treat depression, and benefits typically build gradually over many months.
A program built to evolve
Depression care is changing faster now than at any point in the last fifty years. New neuromodulation protocols, biomarker- and imaging-guided targeting, novel rapid-acting medications, and psychedelic-assisted therapies are all moving through late-stage research. Our program is deliberately structured to adopt new treatments as the evidence grows and regulatory approval arrives — so patients have access to what works now, and to what is coming next, without having to start over somewhere else.
Who we see
We welcome referrals from primary care clinicians, psychiatrists, and other psychiatric prescribers. Patients typically come to us after two or more antidepressants have not brought sufficient relief, or when depression is severe enough that a faster-acting treatment is needed. Existing treatment relationships are preserved: we work alongside current prescribers and therapists.
If depression has outlasted the treatments tried so far, the next step is not to try harder — it is to try differently. Have your clinician place a referral to schedule a consultation.